Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Thol

Showing results (41-50 of 126) with videos related to

Pageof 13
Sort By:
Experimental Hematology & Oncology|October 29, 2025
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolutionRaphael Hablesreiter, Paulina M Strzelecka, Klara Kopp, et al.
RNA (New York, N.Y.)|August 6, 2016
Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulatorsJinsong Qiu, Bing Zhou, Felicitas Thol, et al.
International Journal of Molecular Sciences|September 23, 2022
Healthy-like CD4<sup>+</sup> Regulatory and CD4<sup>+</sup> Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte InfusionJessica Schneider, Leonie Kuhlmann, Yankai Xiao, et al.
Blood Advances|January 20, 2022
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosisNico Gagelmann, Christine Wolschke, Rachel B Salit, et al.
British Journal of Haematology|March 31, 2015
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutationsWalter Fiedler, Sabine Kayser, Maxim Kebenko, et al.
Blood|April 28, 2010
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemiaFelicitas Thol, Frederik Damm, Katharina Wagner, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Nature Genetics|January 17, 2017
Precision oncology for acute myeloid leukemia using a knowledge bank approachMoritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, et al.
European Journal of Haematology|September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patientsSabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Blood|April 26, 2024
Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantationClara Philine Wienecke, Bennet Heida, Letizia Venturini, et al.
Pageof 13

Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Experimental Hematology & Oncology|October 29, 2025
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolutionRaphael Hablesreiter, Paulina M Strzelecka, Klara Kopp, et al.
RNA (New York, N.Y.)|August 6, 2016
Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulatorsJinsong Qiu, Bing Zhou, Felicitas Thol, et al.
International Journal of Molecular Sciences|September 23, 2022
Healthy-like CD4<sup>+</sup> Regulatory and CD4<sup>+</sup> Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte InfusionJessica Schneider, Leonie Kuhlmann, Yankai Xiao, et al.
Blood Advances|January 20, 2022
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosisNico Gagelmann, Christine Wolschke, Rachel B Salit, et al.
British Journal of Haematology|March 31, 2015
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutationsWalter Fiedler, Sabine Kayser, Maxim Kebenko, et al.
Blood|April 28, 2010
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemiaFelicitas Thol, Frederik Damm, Katharina Wagner, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Nature Genetics|January 17, 2017
Precision oncology for acute myeloid leukemia using a knowledge bank approachMoritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, et al.
European Journal of Haematology|September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patientsSabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Blood|April 26, 2024
Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantationClara Philine Wienecke, Bennet Heida, Letizia Venturini, et al.
Pageof 13